Skip to content Skip to footer
Subscribe Now
Akesobio
NEWS

Akeso Reports First Patient Dosing in P-II (COMPASSION-36) Trial of Cadonilimab for PD-1 Treatment-Resistant Hepatocellular Carcinoma (HCC)

Shots: Akeso has dosed its first patient with cadonilimab + lenvatinib in P-II (COMPASSION-36/AK104-225) trial against lenvatinib for the treatment of advanced HCC in pts previously treated with Tecentriq & Avastin; study is ongoing in the US, EU & China Cadonilimab has also shown superior efficacy in combination regimens, incl. 100% DCR with FOLFOX-HAIC in resectable multinodular HCC…
September 15, 2025

Read more

NEWS

Pilatus Biosciences Collaborates with Roche to Evaluate PLT012 & Tecentriq Combination for Hepatocellular Carcinoma (HCC)

Shots: Pilatus Biosciences & Roche have entered into a clinical trial collaboration to evaluate PLT012 + atezolizumab for HCC pts Under the collaboration, Roche will supply atezolizumab (Tecentriq) for Pilatus' P-I study of PLT012 in combination therapy for HCC, with plans to expand to other cancers PLT012 is a humanized mAb that blocks CD36-driven lipid uptake, targeting…
August 14, 2025

Read more

PharmaShots Interview Mahesh Karande, CEO of Omega Therapeutics Shares Insights from the Preclinical Data Presented at the AACR 2022
VIEWPOINTS

PharmaShots Interview: Mahesh Karande, CEO of Omega Therapeutics Shares Insights from the Preclinical Data Presented at the AACR 2022

Shots: Mahesh talked about the data presented on its lead candidate in hepatocellular carcinoma at the AACR 2022 Mahesh also spoke about Omega’s drug-development platform that identifies and targets specific and unique DNA sequences of regulatory elements  The interview gives a profound grip on Omega’s development strategies to use mRNA therapeutics as a new class…
July 19, 2022

Read more